Placental ALLO levels rise during pregnancy and peak as fetuses approach full term
Just as a runner steadily builds up endurance in order to peak at just the right time, the placenta carefully calibrates how much of the hormone allopregnanolone (ALLO) it produces during pregnancy. The placenta ramps up ALLO production in the second trimester of pregnancy and achieves peak production just as fetuses approach full term, according to multi-institutional research presented during the Pediatric Academic Societies (PAS) 2018 annual meeting.
The placenta is the source of more than 200 different hormones that each uniquely contribute to the smooth running of the pregnancy and the fetus' overall health.
ALLO, a progesterone derivative, may protect the developing fetal brain in pregnancies compromised by such conditions as high blood pressure. Researchers know ALLO is made in the adult brain in response to stress and modulates neuronal excitability. Less is known about how placental ALLO levels evolve during pregnancy and in newborns shortly after birth.
Anna Penn, M.D., Ph.D., a neonatologist/neuroscientist at Children's National Health System, and colleagues created a designer experimental model to study how premature loss of ALLO alters orderly brain development. Knowing more about the interplay between ALLO and normal development of the cortex, the outer layer of the cerebrum, is a first step that could lead to strategies to rescue this vital brain region.
"The cortex is basically the brain's command-and-control center for higher functions. In our experimental model, it develops from the middle of gestation through to the end of gestation. If ALLO levels are disrupted just as these cells are being born, neurons migrating to the cortex are altered and the developing neural network is compromised," says Dr. Penn, senior author of the research presented at PAS 2018. "We're concerned this same phenomenon occurs in human infants whose preterm birth disrupts their supply of this essential hormone."
To better understand the human placental hormone pattern, the research team analyzed cord blood or serum samples collected within the first 36 hours of life for 61 preterm newborns born between 24 to 36 gestational weeks. They compared those preemie samples with samples drawn from 61 newborns carried to term who were matched by race, gender, size for gestational age, delivery method and maternal demographics.
They used liquid-chromatography-tandem mass spectrometry, a technique that can precisely analyze trace levels of compounds, to compare levels of 27 different steroids, including ALLO and its precursors as well as better-known adrenal gland hormones, such as cortisol and 17-Hydroxyprogesterone.
"Pregnancies complicated by hypertension tended to correlate with lower ALLO levels, though this finding did not reach statistical significance. This suggests that ongoing placental dysfunction and ALLO loss, not the increase that we expected to be caused by stress, may alter cortical development in these pregnancies and put babies at risk," Dr. Penn adds. "In addition, having the largest neonatal sample set to date in which multiple steroid hormones have been measured can provide insight into the shifting hormone patterns that occur around 36 weeks gestation, just prior to term. Hopefully, restoring the normal hormonal milieu for preemies or other at-risk newborns will improve neurological outcomes in the future."
Provided by Children's National Medical Center